US Patent 5,789,449: Claim Scope, Expiration, Orange Book Status, and Competitive Patent Landscape

US Patent 5,789,449 covers methods of treating selected psychiatric symptoms, including anger, rejection sensitivity, and low mental or physical energy, with serotonin reuptake blockers. The claims expressly identify fluoxetine and sertraline and extend the method to psychiatric symptoms associated with premenstrual disorders.

The patent is a method-of-treatment patent, not a compound, formulation, manufacturing, or delivery-system patent. Its commercial value was concentrated in fluoxetine and sertraline treatment protocols, particularly premenstrual dysphoric or premenstrual psychiatric symptoms. The patent term has ended under the ordinary 20-year rule applicable to post-June 1995 patent filings, so it does not presently block generic fluoxetine, sertraline, or other SSRI products.

What does US Patent 5,789,449 cover?

The patent covers administering a nontoxic dose of a serotonin reuptake blocker to treat specified psychiatric symptoms. Independent claim 1 is directed to general psychiatric symptoms. Independent claim 5 is directed to psychiatric symptoms associated with premenstrual disorders.

Claim	Subject matter	Key limitation
1	Treatment of psychiatric symptoms	Symptoms must include anger, rejection sensitivity, or lack of mental or physical energy
2	Claim 1 composition selection	Lists specified serotonin reuptake blockers and salts
3	Narrowed active ingredients	Fluoxetine or sertraline
4	Fluoxetine dosage	About 2 mg to about 80 mg daily
5	Premenstrual-disorder treatment	Same three symptom categories in a premenstrual context
6	Claim 5 composition selection	Adds norfluoxetine to the listed agents
7	Narrowed active ingredients	Fluoxetine or sertraline
8	Fluoxetine dosage	About 2 mg to about 80 mg daily

The claims do not require a particular tablet, capsule, liquid, extended-release formulation, dosage schedule, manufacturing process, patient age, diagnostic test, or biomarker.

How broad are the independent claims?

Claims 1 and 5 are relatively broad because they do not limit treatment to a named disease such as major depressive disorder, premenstrual dysphoric disorder, generalized anxiety disorder, or obsessive-compulsive disorder.

Claim 1 requires four principal elements:

A patient.
Administration of a serotonin reuptake blocker.
A nontoxic dose.
Treatment of anger, rejection sensitivity, or lack of mental or physical energy.

Claim 5 adds a disease-context requirement. The symptoms must be associated with premenstrual disorders. That limitation narrows the claim but also creates a potentially important infringement question: whether the accused product or prescriber treats symptoms as part of a recognized premenstrual condition rather than treating general depression or anxiety.

The phrase “nontoxic dose” is functional and context-dependent. It does not establish a fixed numerical boundary. For fluoxetine, dependent claims 4 and 8 provide a specific approximate daily adult dose range of 2 mg to 80 mg, but the independent claims are not expressly limited to that range.

What drugs are listed in the patent claims?

The claims identify the following serotonin reuptake blockers:

Fluoxetine
Norfluoxetine, in claims 6 through 8
Zimelidine
Fluvoxamine
Sertraline
Indalpine
Citalopram
Femoxetine
Paroxetine
Alaproclate

Claims 1 and 5 use the broader functional category of “serotonin re-uptake blocker.” Claims 2 and 6 then provide closed lists of named agents. The drafting distinction matters. An accused product containing an SSRI not named in the list could still raise a claim 1 or claim 5 issue if it falls within the broader functional language, although claim construction would determine whether the term covers the relevant mechanism and pharmacology.

The claims also cover pharmaceutically acceptable salts of the listed agents. They do not expressly claim prodrugs, metabolites, combinations, dosage forms, or nonpharmaceutical administration systems.

What is the scope of the fluoxetine claims?

Claims 3, 4, 7, and 8 create the most commercially relevant fluoxetine coverage.

The fluoxetine claims reach:

Treatment of anger.
Treatment of rejection sensitivity.
Treatment of low mental or physical energy.
Treatment of those symptoms in association with premenstrual disorders.
Daily adult doses from approximately 2 mg to 80 mg.

The claims do not require fluoxetine to be administered continuously throughout the menstrual cycle. They also do not expressly require luteal-phase dosing, intermittent dosing, a specific treatment duration, or a particular diagnostic threshold.

This leaves several potential design-around or claim-construction issues:

Issue	Relevance
Drug selection	A non-listed serotonin-modulating agent may avoid claims 2 and 6 but not necessarily claims 1 and 5
Symptom characterization	Treatment for depression without targeting the claimed symptoms may affect infringement analysis
Premenstrual association	General psychiatric treatment may avoid claim 5 if the symptoms are not linked to a premenstrual disorder
Dose	Fluoxetine doses outside 2 to 80 mg may avoid claims 4 and 8 but not necessarily claims 1 and 5
Administration schedule	Continuous versus intermittent dosing is not expressly required
Formulation	Conventional and modified-release forms may fall within the method claims if the underlying treatment limitations are met

What is the scope of the sertraline claims?

Sertraline is expressly included in claims 2, 3, 6, and 7. Unlike fluoxetine, no separate sertraline dose range appears in the claims.

The sertraline claims therefore depend principally on:

Use of sertraline or a pharmaceutically acceptable salt.
Treatment of one of the three specified psychiatric symptoms.
For claims 5 through 7, an association with a premenstrual disorder.

The absence of a sertraline-specific dosage limitation makes the claims potentially broader in dose than the fluoxetine claims. The claims still require the “nontoxic dose” limitation and the specified symptom categories.

What formulations are protected by US Patent 5,789,449?

The patent does not contain an express formulation claim. It does not independently protect:

Immediate-release tablets.
Capsules.
Oral solutions.
Delayed-release products.
Extended-release products.
Fixed-dose combinations.
Transdermal systems.
Depot injections.
Manufacturing processes.
Packaging or dosing devices.

A formulation could be implicated indirectly if it is used in a method satisfying the asserted treatment claim. The patent does not, however, create formulation exclusivity for fluoxetine or sertraline.

This distinction is important for generic entry. A generic manufacturer could market a conventional fluoxetine or sertraline dosage form after applicable product patents and regulatory exclusivities expired, subject to the approved-label and induced-infringement analysis applicable at the time of launch.

What method-of-use rights does the patent provide?

The patent is exclusively a method-of-use patent in the claims supplied. It does not claim the chemical structure of fluoxetine, sertraline, or the other named agents.

Its method-of-use coverage is divided into two commercial categories:

General psychiatric symptoms

Claims 1 through 4 cover treatment of the three specified symptoms without expressly requiring a premenstrual diagnosis.

Premenstrual psychiatric symptoms

Claims 5 through 8 cover the same symptoms when associated with premenstrual disorders.

The second category is narrower because it requires the premenstrual association. It is also more closely related to the later commercial development of fluoxetine for premenstrual dysphoric disorder and related premenstrual symptoms.

When did US Patent 5,789,449 lose exclusivity?

US Patent 5,789,449 issued on August 4, 1998. Its effective filing date was in the post-June 8, 1995 period, making the ordinary patent term 20 years from the earliest effective nonprovisional filing date rather than 17 years from issuance.[1]

On that basis, the patent expired during the 2010s, generally identified in public patent records as having reached the end of its ordinary term in approximately 2016. Any patent-term adjustment, terminal disclaimer, or continuity issue would control the precise expiration date. The patent is no longer a live barrier to current generic development.

Patent expiration ends enforceable patent rights. It does not erase historical infringement exposure that may have accrued before expiration, subject to applicable limitation periods and litigation facts.

What is the FDA and Orange Book status?

The FDA approved Prozac, containing fluoxetine hydrochloride, in 1987 for major depressive disorder.[2] Sertraline was approved later and marketed as Zoloft for several psychiatric indications.[3]

The FDA subsequently approved fluoxetine for premenstrual dysphoric disorder under the Sarafem brand.[4] The approved indication and product-label language were commercially important because method-of-use patents often depend on the relationship between the claimed use and the product’s labeling.

The Orange Book does not transform every patent mentioning an approved drug into an Orange Book-listed patent. Listing generally depends on the NDA holder’s submission and FDA review under applicable listing rules. A patent may be technically relevant to a drug without appearing as a current Orange Book barrier.

For present commercial purposes:

US Patent 5,789,449 is expired.
Fluoxetine has long had generic competition.
Sertraline has long had generic competition.
The patent does not create current product, formulation, or manufacturing exclusivity.
Any historical Orange Book listing would not preserve enforceable exclusivity after patent expiration.

Were there Paragraph IV challenges to this patent?

A Paragraph IV certification applies when an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. The principal historical generic challenges involving fluoxetine and sertraline focused on compound, formulation, or other listed product patents rather than solely on the method claims of US 5,789,449.

The supplied patent claims are method claims. Under Hatch-Waxman, the commercial significance of a method patent depends on whether it was listed against an approved drug product and whether the generic labeling directs the claimed use.[5]

A generic applicant could address an applicable listed method patent through:

A Paragraph IV certification.
A section viii statement carving out the patented method from labeling.
A label design that omits the protected indication, where legally and regulatorily permissible.
A post-expiration launch after the patent term ends.

The record associated with this patent does not establish a current Paragraph IV barrier. Any historical certification or litigation would require review of the relevant ANDA, Orange Book editions, and court docket.

What patent litigation or settlement agreements affected the patent?

The principal commercial disputes in fluoxetine centered on generic entry, product patents, and later-label or indication issues. The patent at issue here was not a compound patent and did not control the basic ability to manufacture fluoxetine.

No current litigation or settlement agreement involving US Patent 5,789,449 creates an ongoing market restriction. Any historical settlement would have expired or become commercially irrelevant with the patent’s expiration unless it contained independent contractual restrictions.

A patent settlement cannot extend the statutory patent term. It may delay launch during the patent term, allocate an entry date, or resolve damages and validity issues, but it does not revive an expired patent.

How strong was the patent estate?

The patent’s strength was mixed.

Strength factor	Assessment
Chemical composition protection	None
Formulation protection	None in the supplied claims
Manufacturing protection	None
Broad psychiatric-use coverage	Relatively broad
Premenstrual-use coverage	Narrower but commercially targeted
Fluoxetine coverage	Strongly explicit
Sertraline coverage	Explicit but without a dose range
Symptom limitation	Creates proof and claim-construction issues
“Nontoxic dose” limitation	Fact-dependent and potentially contestable
Current enforceability	None after expiration

The patent’s strongest historical position was against a product or prescribing practice expressly directed to fluoxetine or sertraline treatment of the claimed premenstrual symptoms. Its weaker position was against a generic product labeled only for unrelated psychiatric conditions, particularly where the generic manufacturer used a legally permissible label carve-out.

How does this patent compare with competing SSRI patent estates?

Drug	Relevant commercial patent profile	Current market position
Fluoxetine	Early compound and product patents; later method-of-use activity for premenstrual disorders	Generic
Sertraline	Original compound and product patent estate; extensive generic entry after expiration	Generic
Fluvoxamine	Compound and product protection historically relevant to obsessive-compulsive disorder	Generic
Citalopram	Compound, salt, and formulation patents had greater product relevance than this patent	Generic
Paroxetine	Compound, formulation, and controlled-release patents created a more complex estate	Generic
Escitalopram	Later enantiomer and formulation patents created a distinct estate from citalopram	Generic

US Patent 5,789,449 is narrower than a compound patent but potentially broader than a single-indication patent because it names symptom categories rather than one formal diagnosis. Its commercial value depended on proving that the accused treatment targeted the claimed symptoms and, for claims 5 through 8, that the symptoms were associated with a premenstrual disorder.

What generic launch risks remain?

There is no current patent-based launch risk from US Patent 5,789,449 itself. The patent’s expiration removes the principal exclusivity issue.

Historical or residual risk would have depended on:

Whether the patent was listed for the relevant FDA-approved product.
Whether the generic label included the claimed premenstrual use.
Whether a prescriber’s conduct could support induced infringement.
Whether other patents covered the product, formulation, or approved indication.
Whether state-law or contractual claims were asserted separately from patent claims.

For current generic fluoxetine and sertraline products, the relevant analysis is product-specific. A company should not treat this expired method patent as a substitute for a complete Orange Book, FDA-label, and patent-family review.

Key Takeaways

US Patent 5,789,449 claims methods using serotonin reuptake blockers to treat anger, rejection sensitivity, and low mental or physical energy.
Fluoxetine and sertraline are expressly named.
Claims 5 through 8 specifically address the same symptoms when associated with premenstrual disorders.
The patent does not claim fluoxetine or sertraline compounds, formulations, manufacturing methods, or delivery devices.
Fluoxetine claims include an approximate daily adult dose range of 2 mg to 80 mg.
The patent expired during the 2010s under the ordinary 20-year patent-term rule.
It is not a current barrier to generic fluoxetine or sertraline entry.
Any historical Paragraph IV or Orange Book relevance would have depended on product-specific listing and labeling.
No biosimilar issue exists because fluoxetine and sertraline are small-molecule drugs, not biologics.
Current market exposure is driven by generic competition and any separate active patents, not by US Patent 5,789,449.

FAQs

Does US Patent 5,789,449 cover Prozac itself?

No. It claims methods of using serotonin reuptake blockers. It does not claim the fluoxetine molecule or the Prozac product as such.

Does the patent cover Sarafem for premenstrual dysphoric disorder?

The claims can reach fluoxetine treatment of specified psychiatric symptoms associated with premenstrual disorders. The patent does not, however, claim every use of Sarafem or every treatment of premenstrual dysphoric disorder.

Can a generic manufacturer sell fluoxetine after this patent expired?

Yes. This patent no longer prevents generic fluoxetine sales. Other patent, regulatory, labeling, or product-specific issues must be assessed separately.

Is norfluoxetine covered for general psychiatric symptoms?

Norfluoxetine is expressly listed in claims 6 through 8, which are directed to premenstrual-disorder-related symptoms. It is not listed in claim 2 for the broader general psychiatric-symptom branch.

Does the patent cover intermittent luteal-phase dosing?

The supplied claims do not expressly require or exclude intermittent, luteal-phase, or continuous dosing. The infringement analysis would depend on whether the dosing regimen satisfies the remaining claim limitations.

References

United States Patent No. 5,789,449, “Method for treating psychiatric symptoms,” issued August 4, 1998. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (1987). Prozac (fluoxetine hydrochloride) prescribing information. FDA.
U.S. Food and Drug Administration. (1991). Zoloft (sertraline hydrochloride) prescribing information. FDA.
U.S. Food and Drug Administration. (2000). Sarafem (fluoxetine hydrochloride) prescribing information. FDA.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, Chapter 2700: Patent term. USPTO.

Details for Patent: 5,789,449

Summary for Patent: 5,789,449